June 10, 2025
Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
Read more
Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
Read moreENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
Read moreVaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology
Read moreCombination of First-in-Class Systemic TLR2/6 Agonist and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with Advanced Solid Tumours
Read moreENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
Read moreVaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination
Read morePathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Read moreAravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
Read moreCerta Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
Read moreBrandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.
Read moreNRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Read moreMyricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
Read moreUp to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+
Read morePathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
Read moreAzura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read moreBrandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator
Read moreEnhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
Read moreVaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
Read moreMyricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
Read moreBrandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease
Read morePathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer
Read moreNew Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance
Read moreCUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Read moreCicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst
Read moreNasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study
Read moreVaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)
Read moreComing in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access
Read moreAravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile
Read moreEntact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Read moreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
Read moreCerta Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases
Read moreAzura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Read moreOpinion: Taking the leap: transitioning from academia to industry – by Christina Kulis
Read moreBrandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics
Read moreMedisanté and George Medicines collaborate to bring Internet of Things (IoT) data collection to decentralised Phase III trial of single-pill triple combination candidate to treat hypertension
Read moreGeorge Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial
Read moreVaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration
Read moreGlyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Read moreAustralian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions
Read morePolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
Read moreClinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
Read moreOpinion: Why Australia needs a national biomedical incubator – Simon Wilkins
Read moreGlyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy
Read moreAllay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform
Read moreHope offered to Australians suffering from a rare incurable fibrotic autoimmune disease, as clinical trials on new treatment commence
Read moreENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise
Read moreIndustry-led leadership programme launched to support women into more top science and innovation roles
Read moreAzura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease
Read moreVaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Read moreQUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats
Read moreAustralian Phase II trial commences for potential world-first treatment of viral conjunctivitis
Read morePerth tech takes out Australian start-up competition to join international finals
Read moreAuspherix Awarded Innovate UK Grant to Treat Life-threatening Respiratory Infections
Read moreLevel 9, 31 Queen Street
Melbourne VIC 3000
Phone +61 3 9657 0700
Email: info@brandonbiocatalyst.com
Suite 2.05, 1 York Street
Sydney NSW 2000
Phone +61 2 8227 7080
Email: info@brandonbiocatalyst.com
